Nuvolos enabled Qanatpharma to overcome key technical hurdles in AI-powered drug discovery by providing an on-demand research environment integrated with GPU and HPC resources. By streamlining complex model setup, eliminating infrastructure bottlenecks, Nuvolos empowered teams to collaborate more efficiently. As a result, Qanatpharma significantly accelerated its therapeutic target validation workflow.
About Qanatpharma
Operating across Canada, Germany, and Switzerland, Qanatpharma focuses on the role of microvascular dysfunction in a range of diseases. The company takes a multidisciplinary approach, including vascular bed models, transcriptomic and proteomic analyses, AI/machine learning techniques, and diverse disease models. Its goal: develop novel therapeutic strategies for major unmet needs such as cognitive decline and hypertension.
The Challenge
Drug discovery remains costly and slow, often taking over a decade and billions of dollars to bring a single therapy to market.
Recent advances, such as AlphaFold, allow researchers to simulate molecular behavior in silico, accelerating discovery while reducing lab costs. Qanatpharma adopted these tools, but scaling them efficiently required powerful infrastructure and reproducible workflows.
The team faced key barriers:
Limited in-house GPU infrastructure.The available hardware couldn’t handle the compute-intensive demands of modern AI models, creating processing delays and limiting scalability.
Complex, time-consuming environment setup. Preparing and configuring software environments for each experiment was slowing down iteration cycles and innovation.
Lack of integrated collaboration and version control. Without unified tools for sharing, tracking, and reproducing results, the team struggled to collaborate efficiently across locations and ensure data integrity.
The Solution
In late 2023, Qanatpharma partnered with Nuvolos to test high-performance AI models like AlphaFold2 and RFdiffusion, overcome key barriers, and accelerate their AI research. With Nuvolos, the team quickly accessed a cloud-based environment built for computational drug discovery. Fast deployment, reproducibility, and integrated collaboration tools let researchers focus on scientific progress instead of managing infrastructure.
Nuvolos helped the team:
Run GPU-powered AI models on demand
Test and refine thousands of hypotheses quickly
Collaborate effectively with versioned sharing and reproducibility
Eliminate infrastructure maintenance burdens
The Outcome
Qanatpharma reduced environment setup time from several days to just a few hours. Their therapeutic target validation process accelerated significantly, supported by reproducible model execution and versioned data tracking.
Nuvolos provided a unified, GPU-enabled platform for:
Scalable AI-driven analysis
Reproducible workflows
Streamlined collaboration
Seamless model-to-result execution
This transformation enabled faster, more efficient pipelines, reduced operational costs, and unlocked competitive advantages like earlier patent filings and reduced time-to-market.
"Nuvolos bridges the IT gap for GPU computing with immediate technical support and custom implementations. Thanks to their expertise, we can focus on therapeutic discovery instead of managing infrastructure."
— Philipp Trepte, Managing Director, Qanatpharma Germany
Explore What’s Possible with Nuvolos
If your team is working on AI-driven research, you know that the earliest stages, from hypothesis testing to model validation, are where speed matters most.
Nuvolos provides a cloud-native, GPU-ready platform that accelerates early discovery by eliminating infrastructure barriers, streamlining collaboration, and ensuring reproducibility from day one.
Let’s connect to explore how Nuvolos can help you turn early ideas into validated results, faster.